Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Seclidemstat |
Synonyms | |
Therapy Description |
Seclidemstat (SP-2577) is a reversible LSD1 (KDM1A) inhibitor that inhibits transcriptional function of EWS/ETS fusions, leading to anti-tumor activity (AACR Annual Meeting 2019, Abstract CT-109, PMID: 32649682). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Seclidemstat | SP2577|SP 2577|SP-2577 | KDM1A Inhibitor 15 | Seclidemstat (SP-2577) is a reversible LSD1 (KDM1A) inhibitor that inhibits transcriptional function of EWS/ETS fusions, leading to anti-tumor activity (AACR Annual Meeting 2019, Abstract CT-109, PMID: 32649682). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03895684 | Phase I | Seclidemstat | Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03600649 | Phase I | Seclidemstat | Clinical Trial of SP-2577 in Patients With Relapsed or Refractory Ewing Sarcoma | Active, not recruiting | USA | 0 |